Silverback Therapeutics develops ImmunoTAC therapies that target previously inaccessible disease pathways, utilizing a novel approach to enhance immune response against specific diseases. This technology addresses the challenge of treating conditions that have eluded traditional therapeutic methods, offering new hope for patients with limited treatment options.
Funding
$85M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ECFounders
Product
Problem
Many patients requiring epinephrine administration face challenges related to needle-related anxiety, device portability, and ease of use, hindering timely and effective treatment. Traditional epinephrine delivery methods may be cumbersome and intimidating, leading to hesitation and potential delays in critical situations.
Solution
ARS Pharma provides a needle-free epinephrine nasal spray, offering a more convenient and accessible alternative for patients and caregivers. This product aims to eliminate the anxiety and difficulties associated with needle-based injections, ensuring rapid and reliable epinephrine delivery. The nasal spray formulation simplifies administration, making it easier for individuals to respond effectively during emergency situations. By addressing the limitations of conventional epinephrine delivery, ARS Pharma empowers patients to manage severe allergic reactions with confidence.
Target Audience
The primary target audience includes individuals with severe allergies, their caregivers, and healthcare providers seeking a more accessible and patient-friendly epinephrine delivery method.
Features
- Needle-free epinephrine delivery via nasal spray
- User-friendly design for easy administration
- Portable and convenient for on-the-go use
- FDA-approved formulation for safety and efficacy
- Addresses needle-related anxiety and hesitation